-
Zwitterionic Lipids Improve mRNA Cancer Vaccines
2026-09-17
The reference study shows that membrane-destabilizing zwitterionic lipids can improve mRNA expression in lymph-node antigen-presenting cells while reducing local LNP reactogenicity in mouse cancer-vaccine models. Its PyCB-based, pH-responsive design offers a mechanistic strategy for balancing endosomal escape, antigen presentation, and tolerability, although clinical translation remains un established.
-
IDH2, Ferroptosis, and TNBC Proliferation
2026-09-17
The reference study identifies IDH2 as a highly expressed metabolic regulator in triple-negative breast cancer and connects its activity to ferroptosis suppression and tumor-cell proliferation. Its combination of tumor-dataset analysis, clinical validation, cell experiments, and mouse models provides a useful framework for studying how redox metabolism shapes TNBC biology, while proliferation assays such as EdU-based DNA synthesis measurement can complement—not replace—ferroptosis-specific readouts.
-
AZD6482 in Causal RNA-Foci Assays
2026-09-16
AZD6482 is a selective PI3Kβ inhibitor that can add isoform-resolved perturbation to mechanistic RNA-foci research. This article explains how to use its biochemical, metabolic, and platelet evidence to design more discriminating assays inspired by recent Myotonic Dystrophy type 1 findings.
-
ARCA Cy3 EGFP mRNA (5-moUTP) Workflow
2026-09-15
Build a two-channel assay that distinguishes mRNA uptake from productive translation in mammalian cells. ARCA capping, 5-methoxyuridine modification, and covalent Cy3 labeling make this reagent useful for delivery screening, intracellular trafficking, and EGFP reporter gene expression analysis.
-
(R,S)-Anatabine: A Model-Selection Guide
2026-09-15
Discover how (R,S)-Anatabine connects amyloid precursor protein processing, BACE-1 regulation, and NF-κB signaling in Alzheimer’s research. This guide emphasizes assay selection, orthogonal validation, and lessons from human tissue models.
-
LEE011 Succinate: pH-Aware Assay Design
2026-09-14
Learn how LEE011 succinate can support reproducible CDK inhibitor studies when pH, dissolution, cell-cycle endpoints, and translational context are considered together. This practical guide interprets the key pH-shift findings and converts them into better cancer research workflows.
-
CKI 7 dihydrochloride: Assay Logic for CK1
2026-09-14
Explore how CKI 7 dihydrochloride can clarify Casein kinase 1 biology without being mistaken for a direct MAPK10 probe. This evidence-led guide connects inhibitor controls, Wnt and circadian assays, apoptosis readouts, and NSCLC metastasis research.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-13
This preprint shows that selected kinase inhibitors can both inhibit p38α MAP kinase activity and accelerate WIP1-mediated dephosphorylation of its activation-loop phosphothreonine. Biochemical and X-ray structural analyses link this effect to an inhibitor-stabilized activation-loop conformation that exposes the phosphatase substrate, suggesting a route to kinase inhibitors with an added signal-termination mechanism.
-
Gramine, the CUL3–MTDH Axis, and TNBC Ferroptosis
2026-09-12
The reference study identifies gramine as an inhibitor of triple-negative breast cancer that acts through a CUL3–MTDH regulatory axis rather than through a nonspecific cytotoxic mechanism alone. By combining target-engagement assays, ferroptosis rescue experiments, genetic knockdown, and xenograft models, the authors connect CUL3-dependent ubiquitination of MTDH with suppression of ferroptosis defenses.
-
Phalloidin B7678: F-Actin Workflow Guide
2026-09-12
Phalloidin (SKU B7678) is a high-affinity F-actin probe for endpoint cytoskeleton visualization in fixed or permeabilized cells, tissue sections, and cell-free assays. It is not appropriate for live-cell imaging or experiments requiring reversible, unperturbed actin remodeling because it stabilizes actin filaments and prevents depolymerization.
-
TET2 Metabolite Binding: Protocol, Findings, and Limits
2026-09-11
Zhang, Cheng, and Ye present an integrated workflow that combines tag-free human TET2 catalytic-domain biochemistry, flow cytometry, and saturation transfer difference NMR to distinguish metabolite binding from functional regulation. The protocol validates known TET2 activators and inhibitors and identifies glyoxylate as a direct-binding candidate, offering a practical framework for connecting metabolism with epigenetic enzyme control.
-
Pregnenolone Carbonitrile: PXR Research Guide
2026-09-11
Pregnenolone Carbonitrile, also called Pregnenolone-16α-carbonitrile, is a rodent PXR agonist used to study xenobiotic metabolism, CYP3A induction, and liver fibrosis pathways. Product specifications and recent PXR research support its use as a mechanistic tool, while species specificity and limited translational evidence define its boundaries.
-
Perphenazine: D2 Antagonist Research Workflows
2026-09-10
Perphenazine supports two complementary research paths: receptor-informed neuropharmacology assays and host-directed antibacterial studies centered on macrophage ROS, autophagy, and lysosomal activity. This workflow guide connects validated cell-death and opioid-tolerance models with practical controls, formulation guidance, and troubleshooting strategies.
-
DAMGO: Reproducible µ-Opioid Assay Design
2026-09-10
This scenario-based guide shows how DAMGO (SKU B6621) can strengthen µ-opioid receptor signaling research while preventing common misinterpretations in viability, receptor activation, and pain-model assays. It links product specifications with published mechanistic evidence to support practical, reproducible experimental decisions.
-
Methylprednisolone: From Inflammation to Bone Models
2026-09-09
Methylprednisolone is more than an anti-inflammatory reagent: it can create a controlled perturbation for connecting glucocorticoid signaling with osteoclast activity and bone architecture. This article explains how to design and interpret a multiscale assay strategy based on a methylprednisolone-induced osteonecrosis model.